Galapagos N.V. (GLPG)
NASDAQ: GLPG
· Real-Time Price · USD
33.04
-0.50 (-1.49%)
At close: Sep 24, 2025, 3:59 PM
33.04
0.00%
After-hours: Sep 24, 2025, 04:10 PM EDT
-1.49% (1D)
| Bid | 32 |
| Market Cap | 2.18B |
| Revenue (ttm) | 275.61M |
| Net Income (ttm) | -284.27M |
| EPS (ttm) | -5.14 |
| PE Ratio (ttm) | -6.43 |
| Forward PE | -21.32 |
| Analyst | Sell |
| Dividends | n/a |
| Ask | 34.3 |
| Volume | 122,024 |
| Avg. Volume (20D) | 267,969 |
| Open | 33.48 |
| Previous Close | 33.54 |
| Day's Range | 32.70 - 33.48 |
| 52-Week Range | 22.36 - 34.17 |
| Beta | 0.03 |
| Ex-Dividend Date | n/a |
About GLPG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GLPG
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GLPG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsGalapagos N.V. is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-7.33%
Galapagos shares are trading lower after the compa...
Unlock content with
Pro Subscription
7 months ago
+2.08%
Galapagos shares are trading lower after the company reported a year-over-year decrease in FY24 EPS results. The company announced it plans to separate into two publicly traded companies.
5 months ago · seekingalpha.com
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patien...